Insights on the Bleeding Disorders Treatment Global Market to 2027 - Featuring Bayer, CSL Behring and Novo Nordisk Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Bleeding Disorders Treatment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Amid the COVID-19 crisis, the global market for Bleeding Disorders Treatment estimated at US$12.7 Billion in the year 2020, is projected to reach a revised size of US$19.9 Billion by 2027, growing at a CAGR of 6.7% over the analysis period 2020-2027.

Hemophilia A, one of the segments analyzed in the report, is projected to record a 6.6% CAGR and reach US$11.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Hemophilia B segment is readjusted to a revised 7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $3.4 Billion, While China is Forecast to Grow at 10.1% CAGR

The Bleeding Disorders Treatment market in the U.S. is estimated at US$3.4 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$4.3 Billion by the year 2027 trailing a CAGR of 10.1% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.6% and 6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Other Types Segment to Record 6.2% CAGR

In the global Other Types segment, USA, Canada, Japan, China and Europe will drive the 5.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.1 Billion in the year 2020 will reach a projected size of US$1.7 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.7 Billion by the year 2027, while Latin America will expand at a 7.4% CAGR through the analysis period.

Select Competitors (Total 46 Featured):

• Bayer AG
• CSL Behring
• Grifols International SA
• Novo Nordisk A/S
• Octapharma AG
• Pfizer, Inc.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• Influencer Market Insights
• World Market Trajectories
• Bleeding Disorders Treatment to Witness Steady Growth
• Hemophilia A to Account for Highest Growth
• Recombinant Coagulation Factor Concentrates to Register Largest Market Share
• Impact of Covid-19 and a Looming Global Recession
• A Prelude into Hemophilia Product Sales of Leading Players
• Select Products in Developmental Stage
• Select Mergers and Acquisitions
• Increasing Prevalence of Bleeding Disorders to Propel Market Prospects
• Prophylactic Treatment in Hemophilia to Support Market Growth
• Emerging Therapies/ Investments to Spur Market Demand
• New Product Launches/ Approvals to Support Market Growth
• Higher Cost of Drugs to Hinder Bleeding Disorders Treatment

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/s0nks6